LY 3475766
Alternative Names: LY3475766Latest Information Update: 28 Oct 2022
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company (India) Pvt. Ltd
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dyslipidaemias
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in USA (IV)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in USA (SC)
- 31 Mar 2021 Eli-Lilly and company completes a phase I trial in Dyslipidaemias (In volunteers) in USA (IV) (SC) (NCT04052594)